Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324706 | 0.87 | CYP2D6 (0.37) | ITGB3ITGA2BCYP2D6CYP1A2ALOX15 | |
| SCHEMBL29326474 | 0.85 | ITGB3 (0.43) | ITGB3ITGA2BCYP2D6CYP1A2ALOX15 | |
| SCHEMBL29324709 | 0.80 | KDM4E (0.44) | CYP2D6CYP1A2ALOX15HSD11B1 | |
| SCHEMBL29324714 | 0.79 | CYP2D6 (0.42) | ITGB3ITGA2BCYP2D6CYP1A2ALOX15 | |
| SCHEMBL15112753 | 0.77 | CYP1A2 (0.41) | CYP2D6CYP1A2ALOX15HSD11B1 | |
| SCHEMBL14436547 | 0.77 | HSD17B10 (0.44) | ITGB3ITGA2BHSD17B10CYP2D6HSD11B1 | |
| SCHEMBL29326374 | 0.76 | ALOX15 (0.45) | HSD17B10CYP2D6CYP1A2ALOX15HSD11B1 | |
| SCHEMBL14671192 | 0.76 | ITGB3 (0.51) | ITGB3ITGA2BHSD17B10CYP2D6EGLN1 | |
| SCHEMBL20793542 | 0.75 | ITGB3 (0.43) | ITGB3ITGA2BHSD17B10CYP2D6CYP1A2 | |
| SCHEMBL29324699 | 0.74 | EPHX2 (0.45) | HSD17B10CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | ITGB3 3806/4885ITGA2B 2931/4885HSD17B10 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.